ReVacc Biotech (https://revaccbio.com) emphasizes infectious disease vaccine and therapeutic development. One example is COVID-19 nanoparticle vaccine candidate REVC-128 we developed has the feature to induce early protection starting at 2 weeks post the immunization by one dose. See publication: https://pubmed.ncbi.nlm.nih.gov/34651563/. There are three technology platforms we developed listed on the website. Grant applications are under review of NIH.